

82% of Next-Gen Immune Therapies Are Chinese

China's fast-track trials are setting a new global standard for AI-driven medical innovation.

Swipe for insights →

THE DATA

82%

In Vivo CAR-T Therapies in Global Trials

Of 140 in vivo CAR-T-cell therapies tested in animals and people worldwide, 82% are being developed by Chinese institutions.

This overwhelming concentration reflects China's unique ecosystem: fast-track regulatory pathways, massive patient pools, and deep integration between academia, hospitals, and industry. The rapid progression from preclinical work to human trials suggests a systemic advantage in clinical validation speed.

Source: Nature · Published September 28, 2026

https://www.nature.com/articles/d41586-026-03004-3?error=cookies_not_supported&code=3f8bc1fb-7a3b-4193-b084-2d20337bd28b



A large indoor vertical farm with rows of strawberry plants and overhead lighting.

01

Speed Is the New Innovation Metric

AgTech AI developers should study China's investigator-initiated trial (IIT) framework as a blueprint for accelerating real-world testing, particularly in precision crop immunity and microbial modulation systems.



02

Regulatory Agility Outpaces Data Volume

AgTech AI Council members should advocate for IIT-style frameworks in agricultural biotechnology—enabling early-stage field trials of AI-driven pest detection, soil microbiome modulation, and autonomous crop response systems—without waiting for full regulatory approval.

MIT, Nvidia, Google & IBM-Trained. Cross Domain-Expert: Quantum, AI, Ethics, Sovereignty, Intelligence, Philanthropy.
Solepoint Planning. VUI AI Cloud Architect. AI Certifications Development. Quant/AI Instructor. Castor Venture Club Member.
Associate Broker.

George Arnold Alexander III, MPA

Director, ALEX Companies

Associate Broker, Alexander Tiffany Southwest, LLC dba ALEX.realestate, et.al.

Texas License #574878-B · Broker License #565194-BB

Broker, ALEX Real Estate · North Carolina License #367733

Independent Broker, ALEX Real Estate · Colorado License #II.100112456

george@alex.realestate · +1 713.918.9951



ALEX Intelligence
deep intelligence

ALEX Real Estate
genius real estate

ALEX Advisory
uncontested strategy

ALEX Cares
purposeful philanthropy

